GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Precipio Inc (FRA:TGK) » Definitions » Cyclically Adjusted PS Ratio

Precipio (FRA:TGK) Cyclically Adjusted PS Ratio : (As of Jun. 10, 2024)


View and export this data going back to . Start your Free Trial

What is Precipio Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Precipio Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Precipio's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precipio Cyclically Adjusted PS Ratio Chart

Precipio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.01

Precipio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.01 0.01

Competitive Comparison of Precipio's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, Precipio's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Precipio's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Precipio's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Precipio's Cyclically Adjusted PS Ratio falls into.



Precipio Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Precipio's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Precipio's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.287/131.7762*131.7762
=2.287

Current CPI (Mar. 2024) = 131.7762.

Precipio Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 4,978.000 100.560 6,523.321
201409 3,154.000 100.428 4,138.517
201412 -8,398.000 99.070 -11,170.484
201503 693.000 99.621 916.682
201506 394.000 100.684 515.672
201509 147.000 100.392 192.956
201512 187.000 99.792 246.934
201603 106.000 100.470 139.029
201606 449.000 101.688 581.853
201609 325.000 101.861 420.448
201612 300.000 101.863 388.099
201703 232.000 102.862 297.214
201706 115.500 103.349 147.269
201709 9.080 104.136 11.490
201712 23.500 104.011 29.773
201803 13.738 105.290 17.194
201806 10.130 106.317 12.556
201809 7.234 106.507 8.950
201812 6.081 105.998 7.560
201903 3.669 107.251 4.508
201906 2.947 108.070 3.593
201909 2.304 108.329 2.803
201912 1.660 108.420 2.018
202003 2.625 108.902 3.176
202006 2.046 108.767 2.479
202009 1.726 109.815 2.071
202012 1.816 109.897 2.178
202103 1.716 111.754 2.023
202106 1.850 114.631 2.127
202109 1.682 115.734 1.915
202112 1.897 117.630 2.125
202203 1.958 121.301 2.127
202206 1.967 125.017 2.073
202209 1.966 125.227 2.069
202212 1.978 125.222 2.082
202303 2.266 127.348 2.345
202306 2.677 128.729 2.740
202309 3.034 129.860 3.079
202312 2.876 129.419 2.928
202403 2.287 131.776 2.287

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Precipio  (FRA:TGK) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Precipio Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Precipio's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Precipio (FRA:TGK) Business Description

Traded in Other Exchanges
Address
4 Science Park, New Haven, CT, USA, 06511
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings.

Precipio (FRA:TGK) Headlines

No Headlines